ES2157881T3 - Metanosulfonato de paroxetina. - Google Patents

Metanosulfonato de paroxetina.

Info

Publication number
ES2157881T3
ES2157881T3 ES00201290T ES00201290T ES2157881T3 ES 2157881 T3 ES2157881 T3 ES 2157881T3 ES 00201290 T ES00201290 T ES 00201290T ES 00201290 T ES00201290 T ES 00201290T ES 2157881 T3 ES2157881 T3 ES 2157881T3
Authority
ES
Spain
Prior art keywords
paroxetine
methanosulfonate
disintegrant
calculated
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00201290T
Other languages
English (en)
Inventor
Andrew Simon Craig
Victor W Jacewicz
David Alan Jones
Deirdre O'keeffe
Michael Urquhart
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2157881(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2157881T3 publication Critical patent/ES2157881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición farmacéutica adaptada para administración oral que comprende 10, 12, 5, 15, 20, 25, 30 ó 40 mg de metanosulfonato de paroxetina por dosis unitaria, calculado sobre la base libre, y un vehículo farmacéuticamente aceptable que comprende un desintegrante.
ES00201290T 1998-07-02 2000-04-10 Metanosulfonato de paroxetina. Expired - Lifetime ES2157881T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (1)

Publication Number Publication Date
ES2157881T3 true ES2157881T3 (es) 2001-09-01

Family

ID=27269380

Family Applications (4)

Application Number Title Priority Date Filing Date
ES99918159T Expired - Lifetime ES2209428T3 (es) 1998-07-02 1999-04-23 Un solvato 1:1 de metanosulfonato de pparoxetina con acetonitrilo.
ES99303151T Expired - Lifetime ES2149044T3 (es) 1998-07-02 1999-04-23 Metanosulfonato de paroxetina.
ES009900849A Expired - Fee Related ES2158778B1 (es) 1998-07-02 1999-04-23 Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
ES00201290T Expired - Lifetime ES2157881T3 (es) 1998-07-02 2000-04-10 Metanosulfonato de paroxetina.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES99918159T Expired - Lifetime ES2209428T3 (es) 1998-07-02 1999-04-23 Un solvato 1:1 de metanosulfonato de pparoxetina con acetonitrilo.
ES99303151T Expired - Lifetime ES2149044T3 (es) 1998-07-02 1999-04-23 Metanosulfonato de paroxetina.
ES009900849A Expired - Fee Related ES2158778B1 (es) 1998-07-02 1999-04-23 Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.

Country Status (34)

Country Link
US (4) US6063927A (es)
EP (5) EP0970955B1 (es)
JP (1) JP2002519422A (es)
KR (1) KR20010053336A (es)
CN (1) CN1127502C (es)
AR (2) AR011759A1 (es)
AT (4) ATE251155T1 (es)
AU (4) AU732211C (es)
BE (3) BE1011664A6 (es)
BR (1) BR9911682A (es)
CA (1) CA2269999A1 (es)
CH (1) CH689805A8 (es)
DE (5) DE29907248U1 (es)
DK (7) DK199900554A (es)
ES (4) ES2209428T3 (es)
FI (2) FI4209U1 (es)
FR (2) FR2780728B1 (es)
GB (5) GB2367003A (es)
GR (3) GR990100140A (es)
HU (1) HUP0102334A3 (es)
IE (5) IES20000894A2 (es)
IL (1) IL140628A (es)
IT (1) IT1312540B1 (es)
LU (1) LU90388B1 (es)
NL (4) NL1011875C2 (es)
NO (1) NO319030B1 (es)
NZ (1) NZ509180A (es)
PL (1) PL345214A1 (es)
PT (4) PT1089996E (es)
SE (1) SE9901462A0 (es)
SI (3) SI1089996T1 (es)
SK (1) SK20262000A3 (es)
TR (1) TR200100054T2 (es)
WO (1) WO2000001694A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP4081820B2 (ja) * 1997-02-27 2008-04-30 味の素株式会社 晶析装置及び晶析方法
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
CA2456233A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
AU2006235230B8 (en) * 2005-04-07 2010-08-26 Chata Biosystems, Inc. Flow path conditioner system
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
BRPI0808354A2 (pt) * 2007-03-09 2014-07-29 Novartis Ag Sais de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4 -il]-pirrola-2,5-diona
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (es) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
CN1068597C (zh) * 1995-05-17 2001-07-18 诺沃挪第克公司 制备4－芳基－哌啶衍生物的方法
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (en) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Process for preparing crystalline paroxetin hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
SK11812000A3 (sk) * 1998-02-06 2001-08-06 Smithkline Beecham Plc Soli paroxetínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
HUP0101215A3 (en) * 1998-03-16 2002-05-28 Smithkline Beecham Plc Chrystalline form of paroxetine
EA200001050A1 (ru) * 1998-04-09 2001-04-23 Смитклайн Бичам Плс Малеат пароксетина
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
HUP0102334A3 (en) 2003-12-29
ATE202777T1 (de) 2001-07-15
BR9911682A (pt) 2001-12-26
EP1089996A1 (en) 2001-04-11
ES2149044T3 (es) 2000-10-16
AT3185U3 (de) 2000-01-25
EP0970955A1 (en) 2000-01-12
FR2780728A1 (fr) 2000-01-07
ES2158778B1 (es) 2002-03-16
DK200000390U1 (da) 2000-12-27
DK1020464T3 (da) 2001-09-24
NL1011875C2 (nl) 2000-03-24
DE69900007D1 (de) 2000-09-07
IES20000893A2 (en) 2001-05-30
AT3185U2 (de) 1999-11-25
NO991944L (no) 2000-01-03
SI1089996T1 (en) 2004-04-30
PL345214A1 (en) 2001-12-03
FI990922A0 (fi) 1999-04-23
GR990100140A (el) 2000-03-31
HUP0102334A2 (hu) 2002-05-29
GB2339428A (en) 2000-01-26
EP1020464B1 (en) 2001-07-04
GB0026487D0 (en) 2000-12-13
ATE195121T1 (de) 2000-08-15
DE19918588A1 (de) 2000-01-27
US20020193406A1 (en) 2002-12-19
CH689805A5 (fr) 1999-11-30
SI0970955T1 (en) 2001-02-28
FI990922L (fi) 2000-01-03
GB2367003A (en) 2002-03-27
GB9909505D0 (en) 1999-06-23
ITMI990866A1 (it) 2000-10-23
CA2269999A1 (en) 2000-01-02
EP1020464A1 (en) 2000-07-19
EP1020463A1 (en) 2000-07-19
NO991944D0 (no) 1999-04-23
AU3619199A (en) 2000-01-24
NL1012271C2 (nl) 1999-09-23
GB2377637A (en) 2003-01-22
GB2336364B (en) 2000-05-10
GB2352395A (en) 2001-01-31
US20020035130A1 (en) 2002-03-21
AU713131B3 (en) 1999-11-25
DK199900554A (da) 2000-01-03
CN1127502C (zh) 2003-11-12
DK1089996T3 (da) 2004-02-09
GB9920332D0 (en) 1999-11-03
GR1003350B (el) 2000-03-29
DE69900007T2 (de) 2001-06-07
NZ509180A (en) 2001-06-29
GR3034328T3 (en) 2000-12-29
AR018197A1 (es) 2001-10-31
DK0970955T3 (da) 2000-10-09
ES2158778A1 (es) 2001-09-01
AU2392899A (en) 2000-01-20
WO2000001694A1 (en) 2000-01-13
SE9901462A0 (sv) 2000-01-03
PT102291A (pt) 2000-05-31
IL140628A (en) 2004-06-20
AU732211C (en) 2004-05-06
ATE251155T1 (de) 2003-10-15
SE9901462L (es)
BE1011664A6 (fr) 1999-11-09
US6063927A (en) 2000-05-16
CN1315949A (zh) 2001-10-03
PT970955E (pt) 2000-11-30
ES2209428T3 (es) 2004-06-16
DK199900234U1 (da) 2000-12-22
US20010023253A1 (en) 2001-09-20
FI4209U1 (fi) 1999-11-10
IE20000633A1 (en) 2001-10-17
IT1312540B1 (it) 2002-04-22
EP1089996B1 (en) 2003-10-01
DE60000003T2 (de) 2002-03-21
DE60000003D1 (de) 2001-08-09
DE29907248U1 (de) 1999-09-09
LU90388B1 (fr) 2001-01-29
GB2352395B (en) 2004-02-11
GB2336364A (en) 1999-10-20
DK199900234U4 (da) 2000-12-22
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
SI1020464T1 (en) 2001-12-31
FR2780728B1 (fr) 2001-02-16
IES20000894A2 (en) 2001-05-30
BE1012403A5 (fr) 2000-10-03
NL1011874C1 (nl) 1999-07-12
JP2002519422A (ja) 2002-07-02
IES990343A2 (en) 2000-01-02
NO319030B1 (no) 2005-06-06
AU732211B2 (en) 2001-04-12
AU713877B3 (en) 1999-12-09
DE69911774T2 (de) 2004-08-05
NL1012272C1 (nl) 1999-07-12
IES81166B2 (en) 2000-05-31
FIU990190U0 (fi) 1999-04-23
DK199900176U3 (da) 1999-08-13
DE69911774D1 (de) 2003-11-06
CH689805A8 (fr) 2000-02-29
FR2802098A1 (fr) 2001-06-15
AR011759A1 (es) 2000-09-13
SE9901462D0 (sv) 1999-04-23
PT1020464E (pt) 2001-10-30
IL140628A0 (en) 2002-02-10
TR200100054T2 (tr) 2001-06-21
EP0970955B1 (en) 2000-08-02
GR3036208T3 (en) 2001-10-31
FI112077B (fi) 2003-10-31
NL1011875A1 (nl) 2000-01-07
EP1288214A1 (en) 2003-03-05
PT102291B (pt) 2002-07-31
KR20010053336A (ko) 2001-06-25
IE990344A1 (en) 2000-05-03
HK1037877A1 (en) 2002-02-22
BE1012420A6 (fr) 2000-10-03
SK20262000A3 (sk) 2001-07-10

Similar Documents

Publication Publication Date Title
ES2157881T3 (es) Metanosulfonato de paroxetina.
CY1109636T1 (el) Συνθεση στοματικης δοσης παρατεταμενης απελευθερωσης
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
BR0015188A (pt) Composições farmacêuticas
DE69831869D1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
HRP980163B1 (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates
PL348734A1 (en) New sustained release oral formulations
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
NO971206D0 (no) Forlenget-frigjöringsformulering
GEP20074047B (en) Pramipexole once-daily dosage form
EE04901B1 (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
UY25544A1 (es) Forma de dosificación de nefazodona
BR0012901A (pt) Medicamentos de ß - carbolina
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
FI951357L (fi) Farmaseuttiset koostumukset, jotka mahdollistavat trimetatsidiinin hidastetun vapautumisen oraalisen annostuksen jälkeen
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
PT1210119E (pt) Composicoes farmaceuticas para administracao oral e topica
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
GEP20063719B (en) Prevention of Migraine Recurrence
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1020464

Country of ref document: ES